WO2010151004A2 - 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 - Google Patents
하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 Download PDFInfo
- Publication number
- WO2010151004A2 WO2010151004A2 PCT/KR2010/003937 KR2010003937W WO2010151004A2 WO 2010151004 A2 WO2010151004 A2 WO 2010151004A2 KR 2010003937 W KR2010003937 W KR 2010003937W WO 2010151004 A2 WO2010151004 A2 WO 2010151004A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemorrhoids
- days
- hydroxychloroquine
- present
- treatment
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to an injectable composition for treatment of hemorrhoids by topical administration containing hydroxychloroquine, and the present invention injects the hemorrhoidal tissue directly by injecting the hemorrhoidal portion to harden the hemorrhoidal tissues, thereby blocking metabolism and ultimately inactivating the hemorrhoidal tissues.
- the present invention relates to an injectable composition for treating hemorrhoids by necrosis of hemorrhoidal tissue.
- Hemorrhoids occupy the first place in inpatient care in Korea, and more than 50% of people over 50 experience it (Seoul National University Hospital), and 5% of all populations in the United States have this disease.
- Hemorrhoids are mainly hemorrhoids, dentitions, perianal abscesses and gingival disorders. The main symptoms are bleeding, hemorrhoids, pain, pain, pruritus and rectal dysfunction. dysfunction, and soiling. Most of the hemorrhoids refers to hemorrhoids mainly.
- Hemorrhoids are the result of an extension and expansion of the skin of the anus and the vasculature under the mucous membrane. It is divided into internal hemorrhoids, external hemorrhoids, and mixed hemorrhoids. It is called the hemorrhoids located on the inner side of the anus about 1.5 cm, and the upper hemorrhoids are formed at the upper part, the outer hemorrhoids are formed at the bottom, and the mixed hemorrhoids are formed on both sides. Initially, only hemorrhoids or external hemorrhoids may be present, but as time passes, hemorrhoids usually progress to mixed hemorrhoids.
- stage 1 hemorrhoids diagnosed with bleeding but without prolapse
- stage 2 with prolapse
- stage 3 with prolapse.
- the degree of progression of external hemorrhoids can be classified according to the incidence of thrombi in consideration of the fairness of the progression of internal hemorrhoids.
- the stage 1 external hemorrhoids are less than 10 days a year due to blood clots
- the stage 2 external hemorrhoids are about 11 to 20 days a year
- the stage 3 external hemorrhoids are more than 3 weeks a year. This is when the fourth stage hemorrhoids occur frequently.
- the general method is to reduce bleeding of internal hemorrhoids in hemorrhoids, or the thrombosis caused by external hemorrhoids and the swelling and pain caused by it are internal medicines, suppositories, and swelling.
- the main ingredient of internal medicine is blood circulation improving agent, and about 10 similar drugs are on the market.
- Suppositories are composed of analgesic anti-inflammatory, antibacterial and astringent components, and 20 kinds of drugs are sold.
- ointments and suppositories are mainly agents containing local anesthetics, steroid preparations and antihistamines.
- administration of local anesthetics or steroids may relieve temporary discomfort but delay the healing of the wound and may cause a variety of systemic and local side effects.
- administration of nonsteroidal anti-inflammatory drugs around the wound is prohibited by slowing the treatment of the disease.
- Patent Application Publication No. 10-2005-0102663 discloses an external preparation for hemorrhoids caused by hemorrhoids and anal fissures, which contains acetylsalicylic acid or a salt thereof as an active ingredient.
- Korean Patent Publication No. 10-0863758 describes a pharmaceutical composition for topical application to acute or chronic anal lacerations, thrombotic internal hemorrhoids or external hemorrhoids, hemorrhoidal diseases, etc. containing adenosine receptor antagonists selected from the group consisting of theophylline or diphylline.
- Korean Patent Laid-Open Publication No. 10-2008-0105857 describes a composition for direct application to a topical surface having an anal rectal disease therapeutic activity containing a puffer fish extract, a puffer fish liver extract, an egg yolk oil, and a cheonung extract.
- the injectable composition for treating hemorrhoids in which the injectable composition containing hydroxychloroquine is injected directly into the affected area to block the metabolism by curing the hemorrhoidal tissues, thereby inactivating the hemorrhoidal tissues and ultimately necrosing the hemorrhoidal tissues. Is unknown to date.
- the topical administration injection composition containing hydroxychloroquine is directly administered to the affected area to penetrate into the root of the hemorrhoids, thereby totally necrosing the tissue cells forming the hemorrhoids, and if the necrosis of the tissue occurs, the affected tissue is 1/3. It shrinks to a degree and consequently peels off.
- the topical injection composition containing hydroxychloroquine of the present invention is directly administered to the affected area to harden the affected tissue to block metabolism and ultimately inactivate the tissue to necrosis of the affected tissue Will happen.
- the present invention relates to a topical administration injectable composition for the treatment of hemorrhoids containing hydroxychloroquine, specifically, 5-10 g of hydroxychloroquine is dissolved in 10 ml of physiological saline for injection, and local anesthetic and antioxidant It relates to an injectable composition for topical administration containing a.
- the hydroxychloroquine preferably contains 1 to 60% w / v of the physiological saline for injection, and more preferably 50% w / v.
- hydroxychloroquine when hydroxychloroquine is prepared by dissolving at 50% w / v of the physiological saline solution for injection, it does not dissolve well and exists as a suspension at room temperature. It is preferable.
- Local anesthetics used in the present invention are used for pain relief when administered directly to the affected area by injection, and preferably contain 1-2% w / v of lidocaine.
- Antioxidants used in the present invention are formulated for formulation stability and preferably contain 0.1% w / v riboflavin.
- the topical administration injectable composition of the present invention can be prepared according to a conventional method by the above-described prescription.
- the present invention is directly administered to the affected area as an injection, preferably 2-3 times at intervals of 3 to 4 days depending on the condition of the patient.
- hemorrhoids hemorrhoids
- Figure 1 is a photograph of the lesion 5 days, 8 days, 40 days after topical administration of the present invention of red 0 (82 years old female).
- FIG. 2 is a photograph of lesions before and after topical administration of the present invention of Kim 0 0 (36 years old), 5 and 26 days after topical administration.
- Figure 3 is a photograph of the lesion 2 days, 5 days, 19 days after the topical administration of the present invention of the right 0 (43 years old male).
- Figure 4 is a photograph of the lesion 3 days, 6 days, 23 days after topical administration of the present invention of Kim 0 0 (56 years old male).
- Figure 5 is a photograph of the lesion 4 days, 13 days after topical administration of the present invention of Kim 0 (42 years old female).
- Figure 6 is a photograph of the lesion 5, 20, 30 days after topical administration of the present invention (0 35 years old).
- Fig. 7 is a photograph of lesions before and after 3 days and 23 days after topical administration of the present invention at the age of 0 (36 years old male).
- Fig. 8 is a photograph of lesions before and after 4 weeks of topical administration of the present invention of women (0 51 years old).
- Hemorrhoids are considered as triangular pyramid.
- hemorrhoids He has suffered from hemorrhoids for over 60 years. Healed in various ways. Recently, I visited a special hospital for hemorrhoids.
- the hemorrhoid size was considered to be not large with 1.0x2.0cm
- Hemorrhoids enlarged to 3.0x4.0cm within 3 days after Hemsol 50 drug administration
- hemorrhoids He suffered from hemorrhoids for many years, then recurred after surgery and developed hemorrhoids like grapes (large 4 hemorrhoids)
- Tissue necrosis begins to peel off on day 10 of administration
- the topical injection composition containing hydroxychloroquine is directly administered to the affected area to infiltrate into the root of the hemorrhoids, thereby totally necrosing the tissue cells constituting the hemorrhoids.
- hemorrhoids can be easily and fundamentally treated without surgical intervention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
- 하이드록시클로로퀸(hydroxychloroquine)을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물.
- 제1항에 있어서, 주사용 생리식염액 10 ml 에 대해 하이드록시클로로퀸을 1 내지 10 g 함유하는 것을 특징으로 하는 치핵 치료를 위한 국소투여용 주사제 조성물.
- 제2항에 있어서, 주사용 생리식염액 10 ml 에 대해 하이드록시클로로퀸을 10 g 함유하는 것을 특징으로 하는 치핵 치료를 위한 국소투여용 주사제 조성물.
- 제1항 내지 제3항 중 어느 한항에 있어서, 국소마취제와 항산화제를 추가로 함유하는 것을 특징으로 하는 치핵 치료를 위한 국소투여용 주사제 조성물.
- 제4항에 있어서, 국소마취제는 리도카인으로 2% w/v 함유하며, 항산화제는 리보플라빈으로 1% w/v 함유하는 것을 특징으로 하는 치핵 치료를 위한 국소투여용 주사제 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10792286.6A EP2468257A4 (en) | 2009-06-23 | 2010-06-18 | INJECTABLE COMPOSITION CONTAINING HYDROXYCHLOROQUINE FOR LOCAL ADMINISTRATION FOR THE TREATMENT OF HEMORRHOIDS |
JP2012517374A JP5342695B2 (ja) | 2009-06-23 | 2010-06-18 | ヒドロキシクロロキンを含有する痔核治療のための局所投与用注射剤組成物 |
BRPI1010072A BRPI1010072A2 (pt) | 2009-06-23 | 2010-06-18 | composição injetavel contendo hidroxicloroquina para administração local para o tratamento de hemorróida |
US13/379,626 US8871228B2 (en) | 2009-06-23 | 2010-06-18 | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids |
RU2012100621/15A RU2530605C2 (ru) | 2009-06-23 | 2010-06-18 | Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя |
AU2010263478A AU2010263478A1 (en) | 2009-06-23 | 2010-06-18 | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids |
CN2010800280712A CN102481252A (zh) | 2009-06-23 | 2010-06-18 | 含有羟基氯喹的用于痔核治疗的局部投药用注射剂组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0055860 | 2009-06-23 | ||
KR1020090055860A KR101067443B1 (ko) | 2009-06-23 | 2009-06-23 | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010151004A2 true WO2010151004A2 (ko) | 2010-12-29 |
WO2010151004A3 WO2010151004A3 (ko) | 2011-05-19 |
WO2010151004A9 WO2010151004A9 (ko) | 2011-07-07 |
Family
ID=43387010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/003937 WO2010151004A2 (ko) | 2009-06-23 | 2010-06-18 | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8871228B2 (ko) |
EP (1) | EP2468257A4 (ko) |
JP (1) | JP5342695B2 (ko) |
KR (1) | KR101067443B1 (ko) |
CN (1) | CN102481252A (ko) |
AU (1) | AU2010263478A1 (ko) |
BR (1) | BRPI1010072A2 (ko) |
RU (1) | RU2530605C2 (ko) |
WO (1) | WO2010151004A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101253565B1 (ko) | 2009-09-22 | 2013-04-11 | 삼성전자주식회사 | 디스플레이 장치 |
KR101698003B1 (ko) | 2016-06-20 | 2017-01-19 | 여오영 | 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
RU2657511C2 (ru) * | 2016-08-15 | 2018-06-14 | Общество с ограниченной ответственностью "ИБМХ-ЭкоБиоТех" (ООО "ИБМХ-ЭкоБиоТех") | Способ получения фармакопейного экстракта |
CN115317483A (zh) * | 2021-12-24 | 2022-11-11 | 南通大学附属医院 | 氯喹及其衍生物在制备PGCCs抑制剂中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050102663A (ko) | 2003-02-21 | 2005-10-26 | 데이고꾸세이약꾸가부시끼가이샤 | 치질환 치료제 |
KR100863758B1 (ko) | 2000-07-31 | 2008-10-16 | 셀러지 파마세우티칼스, 인크 | 항문직장 장애의 치료 조성물 및 방법 |
KR20080105857A (ko) | 2007-06-01 | 2008-12-04 | 주식회사 비앤씨엘 | 치질환 및 기타 항문 직장 질환 치료 활성을 가지는조성물과 이의 제조 방법 및 이를 이용한 치질환 치료제 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
DE19634313A1 (de) * | 1996-08-24 | 1998-02-26 | Behringwerke Ag | Methode zur Stabilisierung von Plättchen |
RU2174396C2 (ru) * | 1997-03-20 | 2001-10-10 | Панацея Биотек Лтд. | Фармацевтическая композиция для подавления и лечения аноректальных и ободочно-кишечных болезней |
US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
JP2003530308A (ja) * | 1999-08-03 | 2003-10-14 | アーヴェーデー.ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用 |
KR100390332B1 (ko) * | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
EP1450803A4 (en) * | 2001-11-09 | 2008-09-03 | Lauren Charous | NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS |
AU2003287100A1 (en) * | 2002-11-08 | 2004-06-03 | Kin-Ping Wong | Compositions containing an active fraction isolated from lycium barbarum and methods of using the same |
AU2003287099A1 (en) * | 2002-11-08 | 2004-06-03 | Kin-Ping Wong | Extract of trapa natans and methods of using the same |
JP4239036B2 (ja) * | 2005-02-21 | 2009-03-18 | ラウト,ラジーブ | 改良薬剤組成物 |
US20080221150A1 (en) * | 2005-08-13 | 2008-09-11 | Shacka John J | Prevention of Neurodegeneration by Macrolide Antibiotics |
-
2009
- 2009-06-23 KR KR1020090055860A patent/KR101067443B1/ko active IP Right Grant
-
2010
- 2010-06-18 JP JP2012517374A patent/JP5342695B2/ja not_active Expired - Fee Related
- 2010-06-18 US US13/379,626 patent/US8871228B2/en not_active Expired - Fee Related
- 2010-06-18 EP EP10792286.6A patent/EP2468257A4/en not_active Withdrawn
- 2010-06-18 CN CN2010800280712A patent/CN102481252A/zh active Pending
- 2010-06-18 AU AU2010263478A patent/AU2010263478A1/en not_active Abandoned
- 2010-06-18 BR BRPI1010072A patent/BRPI1010072A2/pt not_active IP Right Cessation
- 2010-06-18 WO PCT/KR2010/003937 patent/WO2010151004A2/ko active Application Filing
- 2010-06-18 RU RU2012100621/15A patent/RU2530605C2/ru not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100863758B1 (ko) | 2000-07-31 | 2008-10-16 | 셀러지 파마세우티칼스, 인크 | 항문직장 장애의 치료 조성물 및 방법 |
KR20050102663A (ko) | 2003-02-21 | 2005-10-26 | 데이고꾸세이약꾸가부시끼가이샤 | 치질환 치료제 |
KR20080105857A (ko) | 2007-06-01 | 2008-12-04 | 주식회사 비앤씨엘 | 치질환 및 기타 항문 직장 질환 치료 활성을 가지는조성물과 이의 제조 방법 및 이를 이용한 치질환 치료제 |
Also Published As
Publication number | Publication date |
---|---|
KR20100137692A (ko) | 2010-12-31 |
BRPI1010072A2 (pt) | 2016-03-15 |
US8871228B2 (en) | 2014-10-28 |
CN102481252A (zh) | 2012-05-30 |
WO2010151004A9 (ko) | 2011-07-07 |
US20120108633A1 (en) | 2012-05-03 |
RU2012100621A (ru) | 2013-07-27 |
WO2010151004A3 (ko) | 2011-05-19 |
EP2468257A2 (en) | 2012-06-27 |
JP5342695B2 (ja) | 2013-11-13 |
RU2530605C2 (ru) | 2014-10-10 |
AU2010263478A1 (en) | 2012-02-02 |
EP2468257A4 (en) | 2014-02-19 |
JP2012530777A (ja) | 2012-12-06 |
KR101067443B1 (ko) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hazen et al. | Management of necrotizing vasculitis with colchicine: Improvement in patients with cutaneous lesions and Behçet's syndrome | |
CN101744833B (zh) | 一种治疗细菌性***炎的药物组合物 | |
Horn et al. | Warfarin-induced skin necrosis: report of four cases | |
RU2221561C2 (ru) | Витамин е и его сложные эфиры для местного лечения патологий слизистой оболочки | |
WO2010151004A2 (ko) | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 | |
JP2000512270A (ja) | 単純ヘルペスの処置のための組成物および方法 | |
WO2014129818A1 (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
CA3013734C (en) | Method and composition for treatment and prevention of broad spectrum virus ailments | |
CN1381259A (zh) | 一种治疗直肠、***疾病的药物 | |
Pietsch et al. | Injury by hypertonic phosphate enema. | |
US20150374644A1 (en) | Therapeutic Composition for the Treatment of Perianal Disorders | |
CN113456736B (zh) | 一种外用止痛愈伤组合药物及制备方法 | |
Meena et al. | A CASE STUDY OF PARTIAL FISTULECTOMY WITH KSHARSUTRA LIGATION IN TRANSSPHINCTERIC FISTULA IN ANO | |
CN110279766A (zh) | 一种复方黄连药剂及其应用 | |
Sudarsa et al. | A case of pemphigus vulgaris in a patient with abdominal tumor as collaborative disease | |
Bholane et al. | CONCEPTS OF PANCHAKARMA IN SHALYA TANTRA | |
CN116327746A (zh) | 异甘草素在制备预防或治疗对乙酰氨基酚所致药物性肝损伤药物中的应用 | |
Bhise et al. | Effect of Yashtimadhu Ghrita Gudapurana on post operative pain management in patients of haemorrhoids and fissure-in-ano with special reference to Shastranipataja Vedana: A conceptual study | |
CN105477015A (zh) | 一种用于肛瘘术后的外用中药洗剂及其制备方法 | |
WO2024078468A1 (zh) | 二苯乙烯衍生物用于预防和或治疗溃疡的用途 | |
CN112438983A (zh) | 积雪草酸的医药用途 | |
CN112438981A (zh) | 羟基积雪草酸制备预防或治疗溃疡性结肠炎药物中的应用 | |
CN116785334A (zh) | 一种治疗***直肠疾病的中药组合物及其应用 | |
Deshpande Shailesh et al. | CASE REPORT eISSN 2348-0173 | |
EP1838313B1 (en) | Pharmaceutical composition comprising nifedipine and mesalazine for the treatment of rectoanal tenesmus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080028071.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792286 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13379626 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517374 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010792286 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 40/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010263478 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012100621 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010263478 Country of ref document: AU Date of ref document: 20100618 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1010072 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1010072 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111222 |